



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-06)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/002,690
Filing Date	12/05/2001
First Named Inventor	Philip Cavanaugh
Group Art Unit	1645
Examiner Name	Ja-Na Hines
Attorney Docket Number	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†*
JH	1	LAGRANGE, J.L. et al., "Demonstration and characterization of EGF receptors in cancer of the uterine cervix", Bull Cancer, 1993, 80: 219-224. ABS	
	2	INOUE, T. et al., "Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials", Journal of Cellular Physiology, 1993, 156: 212-217.	
	3	CAVANAUGH, P.G., and NICOLSON, G.L., "The selection of a metastatic rat mammary adenocarcinoma cell line from a low metastatic parental population by an in vitro process based on cellular ability to proliferate in response to transferrin", Journal of Cellular Physiology, 174, 48-57, 1998.	
	4	CAVANAUGH, P.G., et al., "Transferrin receptor overexpression enhances transferrin responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line", Breast Cancer Research and Treatment, 56, 203-217, 1999.	
	5	GORDON, I.L. "Scatchard analysis of fluorescent concanavalin A binding to lymphocytes", Cytometry, 1995, 20, 238-244.	
	6	PALUPI, N.S. et al., "Bovine beta-lactoglobulin receptors on transformed mammalian cells (hybridomas MARK-3): characterization by flow cytometry", J Biotechnol, 2000, 78, 171-184.	
	7	SAMUEL D. et al., "A sensitive method of detecting proteins on dot and Western blots using a monoclonal antibody to FITC", J Immunol Methods, 1988, 107, 217-224.	
	8	HASELBACK, A. et al., "Structural characterization of glycoprotein carbohydrate chains by using digoxigenin-labeled lectins on blots", Analytical Biochemistry, 1990, 191, 25-30.	
	9	HASELBACK, A and HOSEL, W. "Detection of proteins and glycoproteins on western blots", in "Nonradioactive labeling and detection of biomolecules", KESSLER, C., ed., 1992, 297-299, Springer-Verlag, Berlin.	
	10	ZHANG, G., et al., "Early detection of apoptosis using a fluorescent conjugate of annexin V", Biotechniques, 1997, 23, 525-531.	
✓	11	LE GALL M., et al., "The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal", Mol Biol Cell, 2000, 11, 1103-1112.	

Examiner Signature	/Jana Hines/ (09/14/2006)	Date Considered	09/14/2006
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-88)
Approved for use through 10/31/88. OMB 0681-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/002,690
Filing Date	12/05/2001
First Named Inventor	Philip Cavanaugh
Group Art Unit	1645
Examiner Name	Ja-Na Hines
Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡
JH		Niedergang F., et al. "Convulxin binding to platelet receptor GPVI: competition with collagen related peptides", Biochem Biophys Res Commun, 2000 273, 246-250.	
JH		Schaffer, L. "A model for insulin binding to the insulin receptor", Eur J Biochem, 1994, 1127-1132.	
JH		Schagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa" Anal Biochem., 1987,166,368-379.	

Examiner Signature	/Jana Hines/ (09/14/2006)	Date Considered	09/14/2006
-----------------------	---------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.